Adult ADHD Care in Northern Ireland Leaves Many Paying Privately
Adults with ADHD in Northern Ireland are facing a striking gap in care: no formally commissioned, publicly funded adult pathway exists, and many patients are being pushed toward private assessment, medication reviews, and ongoing prescriptions. For people who need long-term treatment, the cost is not occasional or incidental. It becomes a permanent bill layered on top of work, family life, and the daily burden of managing symptoms that often affect organisation, concentration, and impulse control.
Rebecca Bryson and her husband, who also has ADHD, pay about £4,000 a year to stay in treatment. Their experience captures the pressure created when specialist review and prescribing are available only through private routes or through arrangements that depend on local capacity. Bryson described the situation as “wildly unfair and kind of inhumane,” and the phrase lands because the financial barrier is not abstract. It directly determines who can remain in care and who cannot.
The clinical consequences extend beyond money. ADHD management in adults usually depends on a combination of diagnosis, medication initiation, and follow-up monitoring, especially when stimulant treatment is involved. When a system cannot absorb adult referrals, people may be left without assessment, left without treatment, or forced to move between private and public care in ways that fragment accountability. For a chronic neurodevelopmental disorder, that fragmentation can be destabilizing at the bedside and at home.
A Service Gap That Starts at Referral and Ends at the Prescribing Desk
Northern Ireland does not have a formally commissioned adult ADHD service. Instead, health trusts manage referrals within existing resources, a model that has produced long waiting lists and, for some patients, effectively closed doors. One patient, Jordan Young, said he tried repeatedly to access services and was told the doors were closed. He eventually went to England for diagnosis, relying on private health insurance from his grandmother to do so.
Young’s account illustrates a system where diagnosis and treatment depend less on clinical need than on geography and personal means. Adults who can pay privately may obtain assessment and medication more quickly. Those who cannot are left waiting, often while symptoms continue to impair work, relationships, and safety. ADHD does not vanish when someone turns 18, yet the transition from child services to adult provision appears to be one of the weakest points in the current setup.
Dr Allen McCullough, a GP with 35 years’ experience, described ADHD diagnosis as an “evolving picture.” His concern is not only demand but information quality. He said some patients attend privately and their GP receives no clear notification about who assessed them or what qualifications that clinician holds. In shared-care arrangements, where a consultant and GP collaborate on prescribing, that lack of clarity becomes a practical obstacle. If the prescribing doctor is expected to carry responsibility, incomplete documentation makes many GPs reluctant to continue medication.
Shared Care Fails When Responsibility Outruns Information
Shared care can work when specialist assessment is clear, communication is reliable, and prescribing responsibility is unambiguous. In ADHD, that process matters because medication needs monitoring and dose adjustments may be required over time. McCullough’s comments point to a difficult medicolegal position: if a GP cannot verify the assessment or the prescriber, continuing treatment carries risk. If the GP refuses, the patient may lose access entirely.
This is where service design becomes clinical safety, not just administration. Adults with ADHD need continuity, especially once treatment has begun. Interruptions in prescribing can lead to loss of symptom control, worsening functioning, and more pressure on already stretched primary care. When the system relies on ad hoc arrangements, responsibility can be clear on paper but blurred in practice.
The situation also reveals why commissioning matters. Without a funded pathway, trusts are forced to use existing resources, and demand continues to outstrip capacity. Waiting lists grow, private diagnosis increases, and GP uncertainty deepens. A service that is not formally commissioned never stabilizes into a predictable route for referral, diagnosis, treatment, and monitoring.
Political Pressure Builds Around an Unfunded Need
Alliance MLA Peter McReynolds said adults with ADHD have been “completely forgotten about” by the Department of Health. He said he had been pushing for a commissioned service since 2024 and argued that such a model would be impactful for patients and save money over time. His case is straightforward: a service that prevents repeated private spending and fragmented care may reduce downstream costs, even if it requires upfront investment.
The Department of Health acknowledged increasing demand and said health trusts manage referrals within existing resources, with demand continuing to exceed capacity and driving people toward private diagnosis. The department also said significant work has been done to understand the level of need for ADHD services. Future commissioning decisions, it said, must be made in the context of overall affordability and wider funding pressures across health and social care.
That balance between need and affordability sits at the centre of the dispute. The reality on the ground is a cohort of adults paying privately for reviews, medication, and prescriptions because the public pathway is not formally built to receive them. For some, that means sacrificing savings or depending on family help. For others, it means no access at all.
A Diagnostic Pathway Without a Reliable Public Endpoint
The most unsettling detail is how ordinary the barriers have become. Adults can obtain a diagnosis as children, but once they reach 18, access may disappear into a patchwork of local arrangements, waiting lists, and cautious prescribing. The system leaves people with a chronic condition dependent on private capacity, local trust resources, and whether a GP is willing to accept shared-care prescribing.
ADHD care is not a luxury service. It is a structured clinical process that should identify impairment, confirm diagnosis, and support safe prescribing and monitoring over time. When that process is missing, adults are not merely inconvenienced; they are pushed into a two-tier model in which treatment is available, but often only to those who can pay. The pressure now falls on whether Northern Ireland can move from improvised access to a commissioned pathway that patients can actually enter and remain in.